Kenneth Nazari, MD
Neurology · Inglewood, CANPI 1417051574
Payments from drug & device makers
Across 120 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$433
- Biogen$397
- EMD Serono, Inc.$186
- Novartis$185
- AstraZeneca$169
- Alnylam Pharmaceuticals Inc.$143
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$472%
- Food & beverage$2,99298%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $433 |
| Biogen | 12 | $397 |
| EMD Serono, Inc. | 7 | $186 |
| Novartis | 10 | $185 |
| AstraZeneca(2 entities) | 7 | $169 |
| Alnylam Pharmaceuticals Inc. | 5 | $143 |
| UCB, Inc. | 5 | $141 |
| Pfizer | 4 | $134 |
| GSK | 4 | $127 |
| Acadia Pharmaceuticals Inc | 6 | $125 |
| Argenx US, Inc. | 4 | $114 |
| Amgen(2 entities) | 3 | $81 |
| Portola Pharmaceuticals, LLC | 1 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $57 |
| Lilly USA, LLC | 3 | $52 |
| Acorda Therapeutics, Inc | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Johnson & Johnson(2 entities) | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Livanova USA, Inc. | 2 | $40 |
| Aquestive Therapeutics, Inc. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Adamas Pharmaceuticals, Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Cycle Pharmaceuticals Inc | 1 | $33 |
| MDD US Operations, LLC | 1 | $33 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| SK Life Science, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| GE HealthCare | 1 | $19 |
| AbbVie | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,039 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 157 | $5,072 |
| Levetiracetam | 72 | $2,994 |
| Rivastigmine | 11 | $2,479 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 20 | $2,186 |
| Carbamazepine | 20 | $1,007 |
| Oxcarbazepine | 25 | $983 |
| Quetiapine Fumarate | 13 | $967 |
| Phenytoin Sodium Extended | 17 | $549 |
| Zonisamide | 18 | $506 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 55 | $506 |
| Lamotrigine | 44 | $462 |
| Duloxetine Hcl | 46 | $424 |
| Divalproex Sodium | 23 | $420 |
| Gabapentin | 50 | $385 |
| Benztropine Mesylate | 23 | $318 |
Paid to pharmacies, not to this prescriber.
Other neurology in Inglewood
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
- Stanley PrusinerSan Francisco$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.